

F. Bossacoma Busquets¹, J.L. Vinent Genestar¹, A. Ruiz Llobet², V.P. Celis Passini²,
 N. Arranz Pasqual¹, A. Comes Escoda¹, J. Arrojo Suárez¹, M. Sánchez Celma¹.

¹Hospital Sant Joan de Déu, Pharmacy, Barcelona, Spain

²Hospital Sant Joan de Déu, Oncology-Haematology department, Barcelona, Spain

BACKGROUND

Approved therapeutic indications for Human Normal Immunoglobulin (HNlg) in paediatric population are: primary immunodeficiency syndromes, Hypogammaglobulinaemia post stem cell transplantation, AIDS with recurrent infections, Primary immune thrombocytopenia (ITP), among other ones. Apart from those, HNlg are also used off label in many clinical indications.

PURPOSE

To describe the use of the HNlg in haematological and oncologic patients of a paediatric teaching hospital.

MATERIAL AND METHODS


We collected and analysed data from all patients treated with HNlg during 8 months in 2017, based on medical history records.

The variables analysed were: clinical area, patient's diagnosis indication (replacement or immunomodulation), and the agreement between prescribed dose and the hospital guidelines.

Our HNlg dosing guidelines are 300-400mg/kg every 3-4 weeks as a replacement therapy and 1000-2000mg/kg of HNlg per course as immunomodulatory indication.

RESULTS

After analysing data from patient's records, 74 patients received HNlg prescribed by an oncologist or haematologist, of which 54 were hematologic patients and 20 were oncologic.



All except one HNlg prescription adhered to our centre dosing policy; the exception was for treating an unresponsive unclassified active infection.

CONCLUSION

Despite HNlg in haematological and oncologic paediatric patients are used off label, there are many indications in daily practice. Further studies are necessary in paediatric patients to increase the evidence and optimize the resources.